Cargando…

Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report

To date, preoperative chemoradiation (CRT) is the standard of care for patients with locally advanced rectal cancer (LARC) regardless of status of mismatch repair. Immunotherapy showed promising results in the neoadjuvant treatment trials in patients with mismatch repair-deficient (dMMR) or high mic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Mai, Yang, Hua, Chen, Ling, Du, Kunli, Zhao, Lina, Wei, Lichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545900/ https://www.ncbi.nlm.nih.gov/pubmed/36212424 http://dx.doi.org/10.3389/fonc.2022.926480

Ejemplares similares

Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021)

Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
por: Ferrari, Linda, et al.
Publicado: (2015)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
por: Ozer, Muhammet, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report
por: Hei, Yue, et al.
Publicado: (2022)

Obesity as an independent predictive factor for pathologic complete response after neoadjuvant chemoradiation in rectal cancer
por: Lee, Soo Young, et al.
Publicado: (2019)

Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H/dMMR rectal cancer: A prospective, multicenter, phase Ib study
por: Li, Xiaofen, et al.
Publicado: (2022)

Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer
por: Seo, Incheol, et al.
Publicado: (2021)

Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients
por: Macchia, Gabriella, et al.
Publicado: (2017)

Histopathological and Haemogram Features Correlate with Prognosis in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation without Pathological Complete Response
por: Huang, Yu-Ming, et al.
Publicado: (2022)

Radiomics for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Observational Trial
por: Shi, Liming, et al.
Publicado: (2023)

Evaluation and Predictive Factors of Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation Therapy
por: Kokaine, Linda, et al.
Publicado: (2021)

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2022)

Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy
por: Wu, Hui, et al.
Publicado: (2023)

Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment
por: Suwanthanma, Weerapat, et al.
Publicado: (2021)

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2023)

Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study
por: Yang, Renfang, et al.
Publicado: (2023)

MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection
por: Kim, Honsoul, et al.
Publicado: (2016)

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
por: Mulet-Margalef, Núria, et al.
Publicado: (2023)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

MR prediction of pathologic complete response and early-stage rectal cancer after neoadjuvant chemoradiation in patients with clinical T1/T2 rectal cancer for organ saving strategy
por: Bae, Heejin, et al.
Publicado: (2020)

Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles
por: Lee, Sung Hwan, et al.
Publicado: (2015)

Pathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer
por: Laughlin, Brady, et al.
Publicado: (2019)

17-Week Delay Surgery after Chemoradiation in Rectal Cancer with Complete Pathological Response
por: Santos, Marisa D., et al.
Publicado: (2015)

Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
por: Inamori, Koji, et al.
Publicado: (2021)

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023)

Neoadjuvant chemoradiation for rectal cancer in patients aged 75 years or older
por: Lombardi, Raffaele, et al.
Publicado: (2009)

Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer
por: Restivo, Angelo, et al.
Publicado: (2015)

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer
por: Dayde, Delphine, et al.
Publicado: (2017)

Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy
por: Liu, Shijin, et al.
Publicado: (2022)

Microbial Characteristics of Locally Advanced Rectal Cancer Patients After Neoadjuvant Chemoradiation Therapy According to Pathologic Response
por: Fan, Qilin, et al.
Publicado: (2021)

A 41-Gene Pair Signature for Predicting the Pathological Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiation
por: Xue, Zhengfa, et al.
Publicado: (2021)

Metformin with neoadjuvant chemoradiation to improve pathologic response in rectal cancer: A pilot phase I/II trial
por: Wong, C.S., et al.
Publicado: (2021)

Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation
por: Cui, Christina Liu, et al.
Publicado: (2021)

Long-Term Outcome of Patients with Complete Pathologic Response after Neoadjuvant Chemoradiation for cT3 Rectal Cancer: Implications for Local Excision Surgical Strategies
por: Belluco, Claudio, et al.
Publicado: (2011)

The value of diffusion kurtosis imaging in assessing pathological complete response to neoadjuvant chemoradiation therapy in rectal cancer: a comparison with conventional diffusion-weighted imaging
por: Hu, Feixiang, et al.
Publicado: (2017)

Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report
por: Cao, Xiaomeng, et al.
Publicado: (2022)

Prediction of biological behavior and prognosis of colorectal cancer patients by tumor MSI/MMR in the Chinese population
por: Yan, Wen-Yue, et al.
Publicado: (2016)

High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
por: Mohamed, Amr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cors4kcjgnb7lk49eckan3945l